

**16.2.8.1.1 Listing of Subjects With First Severe COVID-19 Occurrence After Dose 1
– Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population – CDC+Protocol**

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date	Protocol/CDC Defined Symptoms
No subject meets the reporting criteria.								
<p>Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.</p> <p>a. Relative day (Rel Day) = date of first symptom - date of last dose before first symptom + 1. b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.</p> <p>PFIZER CONFIDENTIAL SDTM Creation: 03NOV2021 (09:31) Source Data: adsympt Table Generation: 08NOV2021 (09:43) (Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File: ./nda2 unblinded/C4591001 S Peds/adsympt l001 sym sev d1 aai ped</p>								

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
BNT162b2 (30 µg)	C4591001 1007 10071409 (USA/13/M)	Dose 1/10	31OCT2020	04NOV2020	Neg	Neg/Neg/Neg	Fever	Pos/, 02NOV2020
	C4591001 1007 10071622 (USA/15/M)	Dose 1/2	31DEC2020	15FEB2021	Neg	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 04JAN2021
	C4591001 1007 10071642 (USA/15/M)	Dose 1/7	10JAN2021	20JAN2021	Neg	Neg/Neg/Pos	New or increased cough	Pos/, 12JAN2021
Placebo	C4591001 1005 10051445 (USA/14/F)*#	Dose 2/77	29MAR2021	02APR2021	Neg	Neg/Neg/Neg	Sore throat New or increased muscle pain New loss of taste or smell	Pos/, 31MAR2021
	C4591001 1006 10061206 (USA/12/M)*#	Dose 2/10	01JAN2021	03JAN2021	Neg	Neg/Neg/Neg	Sore throat Fever	Pos/, 01JAN2021
	C4591001 1006 10061214 (USA/14/M)*#	Dose 2/114	15APR2021	19APR2021	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 22APR2021
	C4591001 1006 10061219 (USA/14/M)	Dose 2/129	01MAY2021	15JUL2021	Neg	Neg/Neg/Neg	New or increased shortness of breath	Pos/, 04MAY2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1006 10061259 (USA/15/F)	Dose 2/7	11JAN2021	24JAN2021	Neg	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 18JAN2021
	C4591001 1006 10061260 (USA/12/F)*#	Dose 2/17	21JAN2021	27JAN2021	Neg	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 21JAN2021
	C4591001 1006 10061284 (USA/14/M)#	Dose 2/8	15JAN2021	16JAN2021	Neg	Neg/Neg/Pos	Diarrhea	Pos/, 18JAN2021
	C4591001 1006 10061285 (USA/14/F)*#	Dose 2/108	29APR2021	27MAY2021	Neg	Neg/Neg/Neg	Sore throat	Pos/, 03MAY2021
	C4591001 1007 10071505 (USA/12/F)	Dose 2/2	29DEC2020	08JAN2021	Neg	Neg/Neg/Pos	New loss of taste or smell	Pos/, 03JAN2021
	C4591001 1007 10071527 (USA/12/M)#	Dose 2/10	07JAN2021	10JAN2021	Neg	Neg/Neg/Pos	Sore throat	Pos/Pos, 10JAN2021
	C4591001 1007 10071559 (USA/14/F)*#	Dose 2/11	14JAN2021	26JAN2021	Neg	Neg/Neg/Neg	Fever	Pos/, 15JAN2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1007 10071603 (USA/13/M)*#	Dose 2/35	22FEB2021	28FEB2021	Neg	Neg/Neg/Neg	Sore throat Fever	Pos/, 23FEB2021
	C4591001 1007 10071613 (USA/13/M)*#	Dose 2/54	13MAR2021	29MAR2021	Neg	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 15MAR2021
	C4591001 1007 10071660 (USA/12/M)*#	Dose 2/74	10APR2021	17APR2021	Neg	Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever	Pos/, 16APR2021
	C4591001 1008 10081871 (USA/14/F)	Dose 1/14	12JAN2021	19JAN2021	Neg	Neg/Neg/Neg	New or increased cough Sore throat New or increased cough	Pos/, 18JAN2021
	C4591001 1008 10081884 (USA/15/F)	Dose 1/19	18JAN2021	26JAN2021	Neg	Neg/Neg/Pos	Sore throat Sore throat	Pos/, 20JAN2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1008 10081919 (USA/14/F)*#	Dose 2/88	26APR2021	05MAY2021	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 28APR2021
	C4591001 1009 10091208 (USA/15/M)*#	Dose 2/66	10JAN2021	14JAN2021	Neg	Neg/Neg/Neg	Sore throat New or increased cough	Pos/, 10JAN2021
	C4591001 1009 10091282 (USA/14/M)*#	Dose 2/42	01FEB2021	02FEB2021	Neg	Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain Sore throat	Pos/, 02FEB2021
	C4591001 1009 10091338 (USA/15/F)	Dose 1/19	01JAN2021	24FEB2021	Neg	Neg/Neg/Pos	New or increased muscle pain New loss of taste or smell Sore throat	Fever Pos/, 02JAN2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
							New or increased cough	
							New or increased muscle pain	
							Sore throat	
	C4591001 1009 10091365 (USA/12/M)*#	Dose 2/79	07APR2021	15MAY2021	Neg	Neg/Neg/Neg	New loss of taste or smell	Pos/, 13APR2021
	C4591001 1009 10091366 (USA/14/F)	Dose 1/9	25DEC2020	01JAN2021	Neg	Neg/Neg/Pos	Fever	Pos/, 28DEC2020
							Chills	
							New or increased muscle pain	
							Sore throat	
	C4591001 1009 10091412 (USA/15/M)*#	Dose 2/29	01MAR2021	03MAR2021	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 01MAR2021
							Sore throat	
	C4591001 1013 10131844 (USA/13/M)*#	Dose 2/144	14MAY2021	16MAY2021	Neg	Neg/Neg/Neg	Fever	Pos/, 19MAY2021
	C4591001 1016 10161316 (USA/15/M)	Dose 1/17	01NOV2020	11NOV2020	Neg	Neg/Neg/Pos	New or increased cough	Pos/, 02NOV2020
							Chills	

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1016 10161319 (USA/12/F)	Dose 2/6	09NOV2020	20NOV2020	Neg	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 10NOV2020
	C4591001 1016 10161379 (USA/13/M)	Dose 1/13	19JAN2021	02FEB2021	Neg	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell Sore throat New or increased muscle pain New loss of taste or smell Sore throat	Pos/ (R1 Pos), 19JAN2021 (29JAN2021)
	C4591001 1039 10391268 (USA/13/F)*#	Dose 2/33	29JAN2021	03MAR2021	Neg	Neg/Neg/Neg	Sore throat Fever New or increased cough	Pos/, 29JAN2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1044 10441264 (USA/14/F)	Dose 2/6	02JAN2021	05JAN2021	Neg	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain	Pos/, 04JAN2021
	C4591001 1044 10441374 (USA/15/M)*#	Dose 2/13	14FEB2021	17FEB2021	Neg	Neg/Neg/Neg	Sore throat Chills	Pos/, 16FEB2021
	C4591001 1057 10571428 (USA/14/M)	Dose 1/5	28DEC2020	02JAN2021	Neg	Neg/Neg/Pos	New loss of taste or smell Vomiting Fever	Pos/, 29DEC2020
	C4591001 1091 10911404 (USA/13/F)*#	Dose 2/27	23JAN2021		Neg	Neg/Neg/Neg	Chills Sore throat New or increased shortness of breath Chills	Pos/, 25JAN2021

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1091 10911407 (USA/12/M)	Dose 2/6	02JAN2021	16JAN2021	Neg	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 06JAN2021
	C4591001 1123 11231468 (USA/15/F)*#	Dose 2/76	27MAR2021	27MAR2021	Neg	Neg/Neg/Neg	New or increased muscle pain Diarrhea	Pos/, 30MAR2021
	C4591001 1123 11231501 (USA/12/F)	Dose 1/18	14JAN2021	02FEB2021	Neg	Neg/Neg/Neg	Fever	Pos/, 19JAN2021
							New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1124 11241248 (USA/13/F)*#	Dose 2/96	11APR2021	14APR2021	Neg	Neg/Neg/Neg	Fever	Pos/, 11APR2021
	C4591001 1126 11261287 (USA/15/M)	Dose 1/15	30DEC2020	11JAN2021	Neg	Neg/Neg/Pos	Sore throat Fever	Pos/, 04JAN2021
	C4591001 1139 11391219 (USA/13/F)*#	Dose 2/72	31MAR2021	14APR2021	Neg	Neg/Neg/Neg	Fever	Pos/, 01APR2021
	C4591001 1142 11421388 (USA/15/M)*#	Dose 2/25	19FEB2021	12MAR2021	Neg	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 19FEB2021
	C4591001 1147 11471280 (USA/12/M)	Dose 1/6	09JAN2021	12JAN2021	Neg	Neg/Neg/Unk	Sore throat	Pos/, 10JAN2021
	C4591001 1150 11501204 (USA/14/M)*#	Dose 2/32	04FEB2021	10FEB2021	Neg	Neg/Neg/Neg	Chills New or increased cough	Pos/, 05FEB2021
	C4591001 1150 11501291 (USA/15/M)	Dose 1/2	12JAN2021	26JAN2021	Neg	Neg/Neg/Neg	Sore throat New or increased cough	Pos/, 13JAN2021
							Sore throat	

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
	C4591001 1152 11521666 (USA/15/F)*#	Dose 2/17	15JAN2021	23JAN2021	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 21JAN2021
	C4591001 1156 11561260 (USA/15/F)*#	Dose 2/82	01FEB2021	05FEB2021	Neg	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 01FEB2021
	C4591001 1156 11561263 (USA/15/M)*#	Dose 2/41	20DEC2020	25DEC2020	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 22DEC2020
	C4591001 1156 11561305 (USA/13/M)*#	Dose 2/141	11MAY2021	25MAY2021	Neg	Neg/Neg/Neg	New loss of taste or smell	Pos/, 14MAY2021
	C4591001 1235 12351243 (USA/15/M)*#	Dose 2/42	09FEB2021	11FEB2021	Neg	Neg/Neg/Neg	New or increased cough	Pos/, 11FEB2021
	C4591001 1270 12701237 (USA/13/F)	Dose 1/13	19JAN2021	20JAN2021	Pos	Neg/Pos/Pos	Sore throat Diarrhea New or increased shortness of breath	Pos/, 21JAN2021

Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown.

090177e1988b77a3\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.1.2 Listing of Subjects With First COVID-19 Occurrence After Dose 1 – Subjects 12 Through 15 Years of Age – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Baseline Serostatus	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date
--	---	---------------------------------	--	--	--------------------------------	--	-------------------------------	--

Note: * indicates subject in the evaluable efficacy (7 days) population with first COVID-19 occurrence from 7 days after Dose 2 and without evidence of infection prior to 7 days after Dose 2. # indicates subject in the evaluable efficacy (7 days) population with first COVID-19 occurrence from 7 days after Dose 2 and with or without evidence of infection prior to 7 days after Dose 2.

a. Relative day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2021 (09:31) Source Data: adsympt Table Generation: 08NOV2021 (09:46)

(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File:

./nda2_unblinded/C4591001_S_Peds/adsympt_1001_sympt_d1_ped_aai

**16.2.8.4.1 Listing of Subjects With Multiple COVID-19 Occurrence After Dose 1
– Subjects 12 Through 15 Years of Age – Dose 1 All-Available Efficacy Population**

Vaccine Group (as Randomized)	Subject (Country/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date
Placebo	C4591001 1270 12701237 (USA/13/F)	Dose 1/13	19JAN2021	20JAN2021	Neg/Pos/Pos	New or increased shortness of breath	Pos/, 21JAN2021
		Dose 1/20	26JAN2021	26JAN2021	Neg/Pos/Pos	Diarrhea	Pos/, 29JAN2021

Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2021 (09:31) Source Data: adsympt Table Generation: 08NOV2021 (11:16)

(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File: ./nda2_unblinded/C4591001_S_Peds/adsympt_multi_cov_d1_aai_ped

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
Placebo	C4591001 1005 10051445 (USA/NEW YORK/14/F)	Dose 2/77	29MAR2021	02APR2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 31MAR2021, B.1.1.7
	C4591001 1006 10061206 (USA/UTAH/12/M)	Dose 2/10	01JAN2021	03JAN2021	Neg/Neg/Neg	Fever	Pos/, 01JAN2021, B.1.400
	C4591001 1006 10061214 (USA/UTAH/14/M)	Dose 2/114	15APR2021	19APR2021	Neg/Neg/Neg	New or increased cough	Pos/, 22APR2021, B.1.1.7
	C4591001 1006 10061260 (USA/UTAH/12/F)	Dose 2/17	21JAN2021	27JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 21JAN2021, B.1.1.29
	C4591001 1006 10061284 (USA/UTAH/14/M)	Dose 2/8	15JAN2021	16JAN2021	Neg/Neg/Pos	Diarrhea	Pos/, 18JAN2021, B.1.142
	C4591001 1006 10061285 (USA/UTAH/14/F)	Dose 2/108	29APR2021	27MAY2021	Neg/Neg/Neg	Sore throat	Pos/, 03MAY2021, B.1.1.519
	C4591001 1007 10071527 (USA/OHIO/12/M)	Dose 2/10	07JAN2021	10JAN2021	Neg/Neg/Pos	Sore throat	Pos/Pos, 10JAN2021, B.1.2
	C4591001 1007 10071559 (USA/OHIO/14/F)	Dose 2/11	14JAN2021	26JAN2021	Neg/Neg/Neg	Fever Sore throat	Pos/, 15JAN2021, B.1.2
	C4591001 1007 10071603 (USA/OHIO/13/M)	Dose 2/35	22FEB2021	28FEB2021	Neg/Neg/Neg	Fever	Pos/, 23FEB2021, B.1.2

090177e1988b77a6\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
	C4591001 1007 10071613 (USA/OHIO/13/M)	Dose 2/54	13MAR2021	29MAR2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/ 15MAR2021, B.1.1.222
	C4591001 1007 10071660 (USA/OHIO/12/M)	Dose 2/74	10APR2021	17APR2021	Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever	Pos/, 16APR2021, QNS
	C4591001 1008 10081919 (USA/MISSOURI/14/F)	Dose 2/88	26APR2021	05MAY2021	Neg/Neg/Neg	New or increased cough Sore throat New or increased cough	Pos/, 28APR2021, B.1.1.7
	C4591001 1009 10091208 (USA/UTAH/15/M)	Dose 2/66	10JAN2021	14JAN2021	Neg/Neg/Neg	Sore throat New or increased cough New or increased shortness of breath	Pos/, 10JAN2021, B.1.2

090177e1988b77a6\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
	C4591001 1009 10091282 (USA/UTAH/14/M)	Dose 2/42	01FEB2021	02FEB2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Chills	Pos/, 02FEB2021, B.1.427
	C4591001 1009 10091365 (USA/UTAH/12/M)	Dose 2/79	07APR2021	15MAY2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 13APR2021, B.1.1.7
	C4591001 1009 10091412 (USA/UTAH/15/M)	Dose 2/29	01MAR2021	03MAR2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 01MAR2021, B.1.2
	C4591001 1013 10131844 (USA/FLORIDA/13/M)	Dose 2/144	14MAY2021	16MAY2021	Neg/Neg/Neg	Fever	Pos/, 19MAY2021, B.1.1.7
	C4591001 1039 10391268 (USA/TEXAS/13/F)	Dose 2/33	29JAN2021	03MAR2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 29JAN2021, B.1

090177e1988b77a6\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
	C4591001 1044 10441374 (USA/VIRGINIA/15/M)	Dose 2/13	14FEB2021	17FEB2021	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain	Pos/, 16FEB2021, B.1.243
	C4591001 1091 10911404 (USA/OHIO/13/F)	Dose 2/27	23JAN2021		Neg/Neg/Neg	New loss of taste or smell Vomiting New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 25JAN2021, B.1.361

090177e1988b77a6\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
	C4591001 1123 11231468 (USA/NEBRASKA/15/F)	Dose 2/76	27MAR2021	27MAR2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 30MAR2021, B.1.2
	C4591001 1124 11241248 (USA/RHODE ISLAND/13/F)	Dose 2/96	11APR2021	14APR2021	Neg/Neg/Neg	Fever Sore throat	Pos/, 11APR2021, B.1.526
	C4591001 1139 11391219 (USA/NORTH CAROLINA/13/F)	Dose 2/72	31MAR2021	14APR2021	Neg/Neg/Neg	Fever New loss of taste or smell Sore throat	Pos/, 01APR2021, B.1.1.7
	C4591001 1142 11421388 (USA/TEXAS/15/M)	Dose 2/25	19FEB2021	12MAR2021	Neg/Neg/Neg	Sore throat	Pos/, 19FEB2021, B.1.2
	C4591001 1150 11501204 (USA/OHIO/14/M)	Dose 2/32	04FEB2021	10FEB2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 05FEB2021, B.1.2
	C4591001 1152 11521666 (USA/CALIFORNIA/15/F)	Dose 2/17	15JAN2021	23JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 21JAN2021, B.1.427

090177e1988b77a6\Final\Final On: 09-Nov-2021 04:12 (GMT)

16.2.8.6 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
	C4591001 1156 11561260 (USA/FLORIDA/15/F)	Dose 2/82	01FEB2021	05FEB2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 01FEB2021, B.1.2
	C4591001 1156 11561263 (USA/FLORIDA/15/M)	Dose 2/41	20DEC2020	25DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 22DEC2020, B.1.369
	C4591001 1156 11561305 (USA/FLORIDA/13/M)	Dose 2/141	11MAY2021	25MAY2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 14MAY2021, B.1.1.7
	C4591001 1235 12351243 (USA/LOUISIANA/15/M)	Dose 2/42	09FEB2021	11FEB2021	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 11FEB2021, B.1.2

Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; QNS = not quantifiable samples; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 02NOV2021 (15:56) Source Data: adsympt Table Generation: 04NOV2021 (14:59)

(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File:

./nda2_unblinded/C4591001_S_Peds/adxb_1001_seq_d2_cov_peds_eval

16.2.8.7 Listing of Subjects 12 Through 15 Years of Age and SARS-CoV-2 Variants With Multiple COVID-19 Occurrence After Dose 1 – Dose 1 All-Available Efficacy Population

Vaccine Group (as Randomized)	Subject (Country/Region/Age in Years/Sex)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
Placebo	C4591001 1270 12701237 (USA/CALIFORNIA/13/F)	Dose 1/13	19JAN2021	20JAN2021	Neg/Pos/Pos	New or increased shortness of breath	Pos/, 21JAN2021, B.1.1.38
		Dose 1/20	26JAN2021	26JAN2021	Neg/Pos/Pos	Diarrhea	Pos/, 29JAN2021, B.1.1.1

Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 02NOV2021 (15:56) Source Data: adsympt Table Generation: 04NOV2021 (14:59)

(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File:

./nda2 unblinded/C4591001 S Peds/adxb 1001 seq d1 mulcov ped aai